The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance

Athena Davenport, B. Lyn-Cook, F. A. Beland, I. P. Pogribny

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

One of the major limitations of chemotherapy is that often, over time, tumor cells become either inherently resistant or develop multidrug resistance to the treatment. Another limitation of chemotherapy is toxicity to normal tissues and adverse side effects. The reasons for the failure of some cancers to respond to chemotherapeutic drugs are not clear but have been attributed to alterations in many molecular pathways, which include drug metabolizing enzymes and drug transporter genes. Alterations in the energy-dependent ATP-binding cassette (ABC) transporter genes have been suggested to confer a drug-resistant phenotype by decreasing the intracellular accumulation of chemotherapeutic drugs via efflux mechanisms. In addition, polymorphisms in UDP- glucuronosyltransferases (UGTs) have been reported to correlate with clinical outcome and drug resistance. In this review, we provide an overview of known polymorphisms within UGTs and ABC transporter genes that have been reported to have altered expression and/or activity in breast cancer. Those polymorphic variants that affect the clinical efficacy and confer drug resistance of chemotherapeutic agents, including hormonal therapies, taxanes, anthracyclines, and alkylating agents, in breast cancer.

Original languageEnglish (US)
Pages (from-to)172-180
Number of pages9
JournalExperimental Oncology
Volume32
Issue number3
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Glucuronosyltransferase
Drug Resistance
Breast Neoplasms
ATP-Binding Cassette Transporters
Pharmaceutical Preparations
Genes
Drug Therapy
Taxoids
Alkylating Agents
Anthracyclines
Multiple Drug Resistance
Neoplasms
Phenotype
Enzymes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance. / Davenport, Athena; Lyn-Cook, B.; Beland, F. A.; Pogribny, I. P.

In: Experimental Oncology, Vol. 32, No. 3, 01.09.2010, p. 172-180.

Research output: Contribution to journalReview article

Davenport, Athena ; Lyn-Cook, B. ; Beland, F. A. ; Pogribny, I. P. / The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance. In: Experimental Oncology. 2010 ; Vol. 32, No. 3. pp. 172-180.
@article{925179ed920f4f6a964c9649bd3d69cd,
title = "The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance",
abstract = "One of the major limitations of chemotherapy is that often, over time, tumor cells become either inherently resistant or develop multidrug resistance to the treatment. Another limitation of chemotherapy is toxicity to normal tissues and adverse side effects. The reasons for the failure of some cancers to respond to chemotherapeutic drugs are not clear but have been attributed to alterations in many molecular pathways, which include drug metabolizing enzymes and drug transporter genes. Alterations in the energy-dependent ATP-binding cassette (ABC) transporter genes have been suggested to confer a drug-resistant phenotype by decreasing the intracellular accumulation of chemotherapeutic drugs via efflux mechanisms. In addition, polymorphisms in UDP- glucuronosyltransferases (UGTs) have been reported to correlate with clinical outcome and drug resistance. In this review, we provide an overview of known polymorphisms within UGTs and ABC transporter genes that have been reported to have altered expression and/or activity in breast cancer. Those polymorphic variants that affect the clinical efficacy and confer drug resistance of chemotherapeutic agents, including hormonal therapies, taxanes, anthracyclines, and alkylating agents, in breast cancer.",
author = "Athena Davenport and B. Lyn-Cook and Beland, {F. A.} and Pogribny, {I. P.}",
year = "2010",
month = "9",
day = "1",
language = "English (US)",
volume = "32",
pages = "172--180",
journal = "Experimental Oncology",
issn = "0204-3564",
publisher = "Morion LLC",
number = "3",

}

TY - JOUR

T1 - The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance

AU - Davenport, Athena

AU - Lyn-Cook, B.

AU - Beland, F. A.

AU - Pogribny, I. P.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - One of the major limitations of chemotherapy is that often, over time, tumor cells become either inherently resistant or develop multidrug resistance to the treatment. Another limitation of chemotherapy is toxicity to normal tissues and adverse side effects. The reasons for the failure of some cancers to respond to chemotherapeutic drugs are not clear but have been attributed to alterations in many molecular pathways, which include drug metabolizing enzymes and drug transporter genes. Alterations in the energy-dependent ATP-binding cassette (ABC) transporter genes have been suggested to confer a drug-resistant phenotype by decreasing the intracellular accumulation of chemotherapeutic drugs via efflux mechanisms. In addition, polymorphisms in UDP- glucuronosyltransferases (UGTs) have been reported to correlate with clinical outcome and drug resistance. In this review, we provide an overview of known polymorphisms within UGTs and ABC transporter genes that have been reported to have altered expression and/or activity in breast cancer. Those polymorphic variants that affect the clinical efficacy and confer drug resistance of chemotherapeutic agents, including hormonal therapies, taxanes, anthracyclines, and alkylating agents, in breast cancer.

AB - One of the major limitations of chemotherapy is that often, over time, tumor cells become either inherently resistant or develop multidrug resistance to the treatment. Another limitation of chemotherapy is toxicity to normal tissues and adverse side effects. The reasons for the failure of some cancers to respond to chemotherapeutic drugs are not clear but have been attributed to alterations in many molecular pathways, which include drug metabolizing enzymes and drug transporter genes. Alterations in the energy-dependent ATP-binding cassette (ABC) transporter genes have been suggested to confer a drug-resistant phenotype by decreasing the intracellular accumulation of chemotherapeutic drugs via efflux mechanisms. In addition, polymorphisms in UDP- glucuronosyltransferases (UGTs) have been reported to correlate with clinical outcome and drug resistance. In this review, we provide an overview of known polymorphisms within UGTs and ABC transporter genes that have been reported to have altered expression and/or activity in breast cancer. Those polymorphic variants that affect the clinical efficacy and confer drug resistance of chemotherapeutic agents, including hormonal therapies, taxanes, anthracyclines, and alkylating agents, in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=77957731197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957731197&partnerID=8YFLogxK

M3 - Review article

VL - 32

SP - 172

EP - 180

JO - Experimental Oncology

JF - Experimental Oncology

SN - 0204-3564

IS - 3

ER -